|
Match
|
Document |
Document Title |
|
|
US20050148512 |
Medical implants and fibrosis-inducing agents
Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between... |
|
|
US20110123577 |
Method Of Delivering Stable Topical Drug Compositions
A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for... |
|
|
US20110046606 |
Catheter injectable depot compositions and uses thereof
Catheter injectable depot compositions are provided that include a bioerodible, biocompatible polymer, a solvent having miscibility in water of less than or equal to 7 wt. % at 25° C., in an... |
|
|
US20100292139 |
TOPICAL DRUG DELIVERY USING PHOSPHATIDYLCHOLINE
The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the... |
|
|
US20070196416 |
Pharmaceutical compositions with enhanced stability
The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention... |
|
|
US20070141145 |
HYDROPHOBIC CORE CARRIER COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS, METHODS OF MAKING AND USING THE SAME
The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The... |
|
|
US20060210599 |
High viscosity liquid controlled delivery system and medical or surgical device
The present invention relates to novel nonpolymeric compounds and compositions that form liquid, high viscosity materials suitable for the delivery of biologically active substances in a... |
|
|
US20060105955 |
Topical drug delivery using phosphatidylcholine
The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the... |
|
|
US20050181004 |
Intravascular devices and fibrosis-inducing agents
Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order... |
|
|
US20050177103 |
Intravascular devices and fibrosis-inducing agents
Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order... |
|
|
US20050147562 |
Medical implants and fibrosis-inducing agents
Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between... |
|
|
US20140315795 |
Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types
The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic... |
|
|
US20120077745 |
Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or... |
|
|
US20090163419 |
Human growth hormone aqueous formulation
A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is... |
|
|
US20070173450 |
PROCESS FOR THE SYNCHRONIZATION OF OVULATION FOR TIMED BREEDING WITHOUT HEAT DETECTION
A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle... |
|
|
US20070099820 |
Polymer-drug conjugates
A conjugate that includes a drug covalently linked to a polymer. Upon administration, the conjugate is digested by an enzyme that is present at the site of administration thereby releasing a... |
|
|
US20060275353 |
Stable topical drug delivery compositions
A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for... |
|
|
US20060153801 |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
A non-polydispersed mixture of conjugates in which each conjugate in the mixture comprises a drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may... |
|
|
US20060127469 |
Methods of delivering stable topical drug compositions
A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for... |
|
|
US20060093557 |
Particulate composition
Nanoparticles are prepared from a colloidal system comprising a continuous phase and micelles, the micelles comprising surfactant material. A microemulsion is formed by admixing the colloidal... |
|
|
US20050069591 |
Injectable, oral, or topical sustained release pharmaceutical formulations
Pharmaceutical formulations and methods are provided for the sustained delivery of a pharmaceutical agent to a patient by injection, by oral administration or by topical administration. The... |
|
|
US20050009847 |
Compounds and methods for increasing neurogenesis
The invention is directed to methods of promoting neurogenesis by contacting neuronal tissue with intracellular cAMP elevating agents and intracellular Ca2+ elevating agents. Novel agents for... |
|
|
US20150374656 |
Compositions and methods of use of phorbol esters
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means... |
|
|
US20140072531 |
METHOD FOR PREPARING MICROPARTICLES WITH REDUCED INITIAL BURST AND MICROPARTICLES PREPARED THEREBY
A method for preparing polymer microparticles with a reduced initial burst, and the polymer microparticles prepared thereby, the method including: contacting polymer microparticles with an alcohol... |
|
|
US20130230598 |
SUSTAINED-RELEASE COMPOSITION OF DRUGS ENCAPSULATED IN MICROPARTICLES OF HYALURONIC ACID
A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased... |
|
|
US20120329714 |
Prolactin Induced Increase in Neural Stem Cell Numbers
The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ,... |
|
|
US20110020458 |
SUSTAINED-RELEASE COMPOSITION OF DRUGS ENCAPSULATED IN MICROPARTICLES OF HYALURONIC ACID
A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased... |
|
|
US20070248686 |
Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same
A suspension of vector particles (PV) based on polyamino acids and have a mean hydrodynamic diameter between 30 and 120 nm, and an insulin load factor of from 5 to 25% of associated insulin volume... |
|
|
US20060188496 |
Intranasal administration of active agents to the central nervous system
A method for delivering a polypeptide to the central nervous system of a mammal is provided. The method involves attaching the polypeptide to an antibody or an antibody fragment and administering... |
|
|
US20140329750 |
Growth Hormones with Prolonged In-Vivo Efficacy
The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin. |
|
|
US20070219131 |
COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER
This invention relates to novel penetrating compositions including one or more effectors included within a water soluble composition, immersed in a hydrophobic medium. The invention also relates... |
|
|
US20050031549 |
Compositions and methods for enhanced mucosal delivery of growth hormone
Pharmaceutical formulations are described comprising at least one growth hormone and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the growth hormone. In... |
|
|
US20120283172 |
MODIFIED PORCINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES
Modified porcine somatotropin polypeptides and uses thereof are provided. |
|
|
US20070275889 |
Gene Expression Technique
The present invention provides a method for producing heterologous protein comprising: (a) providing a host cell comprising a 2 μm-family plasmid, the plasmid comprising a gene encoding a protein... |
|
|
US20050032702 |
Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
Use of a substance that upon administration will lead to increased concentrations of growth hormone, such as growth hormone, a functionally equivalent analogue thereof or a substance that will... |
|
|
US20070065404 |
Uses of humans zven proteins and polynucleotides
The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility... |
|
|
US20070191283 |
Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or... |
|
|
US20060166871 |
Medical compositions containing ghrelin
It is provided a pharmaceutical composition stably containing ghrelin or its derivative, which is an endogenous growth hormone secretagogue (GHS) to a growth hormone secretagogue-receptor (GHS-R),... |
|
|
US20060062758 |
Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds
Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian... |
|
|
US20050152980 |
Pharmeutical microparticles
Microparticles consisting of (a) a matrix with a mixture of (a1) at least one hydrophobic, biologically degradable polymer and (a2) optionally at least one water-soluble polymer, (b) a... |
|
|
US20050118272 |
Micronized pharmaceutical or nutraceutical powder with immediate release
The invention concerns a micronized pharmaceutical or nutraceutical powder with immediate release having a grain size distribution of not more than 100 μm, and comprising the combination of at... |
|
|
US20050261201 |
Method of reducing C-reactive protein using growth hormone secretagogues
The present invention relates to a method of reducing C-reactive protein in a subject in need of treatment thereof, wherein the subject is at risk of having or the subject has already had a... |
|
|
US20110123625 |
Compositions of Less Immunogenic and Long-Circulating Protein-Lipid Complexes
Provided are lipidic particles comprising phosphatidylcholine, phosphatidylinositol and cholesterol. Also provided are compositions comprising the lipidic particles and having associated therewith... |
|
|
US20100247594 |
DELIVERY OF DRY FORMULATIONS OF OCTREOTIDE
Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require... |
|
|
US20080226730 |
PARTICLES FOR INHALATION HAVING RAPID RELEASE PROPERTIES
The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin... |
|
|
US20070243192 |
Growth hormone receptor antagonist cancer treatment
The present invention provides methods and compositions for treating tumorigenic cells (e.g., mammary progenitor cancer cells), with growth hormone receptor antagonists (e.g., Pegvisomant), as... |
|
|
US20060193825 |
Pharmaceutical formulations for sustained drug delivery
The present invention provides pharmaceutical formulations comprising a solid ionic complex of a polypeptide having an isoelectric point lower than physiological pH and an anionic carrier... |
|
|
US20050025806 |
Sustained release pharmaceutical composition
A sustained release delivery apparatus including a silicone support material formed from a methyl-vinyl siloxane polymer including a fumed silica as a reinforcing filler; a pharmaceutically active... |
|
|
US20140162944 |
CONTROLLED RELEASE PEPTIDE FORMULATIONS
The present invention relates to compositions forming a low viscosity mixture of: a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b) 20-80 wt. % of at least one phosphatidyl... |
|
|
US20080200383 |
Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
The present disclosure is directed to stable pharmaceutical formulations and uses thereof. |